DOCSLIB.ORG

Shareholders 2017 Letter to Shareholders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Shareholders 2017 Letter to Shareholders LETTER TO SHAREHOLDERS 2017 LETTER TO SHAREHOLDERS Robert A. Bradway, Chairman and Chief Executive Officer, Amgen Inc. To My Fellow Shareholders, Amgen had another successful year in 2017, serving Today, we are seeing intensifying competition across patients around the world with innovative medicines and our business from large, well-established players and enabling them to live longer, healthier lives. smaller, nimble newcomers. We see a policy and access environment around the world that is increasingly With revenues of $22.8 billion, we achieved record challenging to innovation. And we are seeing traditional non-GAAP earnings per share of $12.58,1 up 8% from roles in the healthcare ecosystem blur as companies the prior year, a record non-GAAP operating margin of enter into unconventional partnerships in an attempt 53.5%,1 and record free cash flow of $10.5 billion.1 to find new ways to succeed. Consistent with our belief in the long-term value of innovation, we invested $3.5 billion1 in research and At a time when so much is changing, it is critical to have 2017 RESULTS development in support of a very promising pipeline a clearly articulated mission, a meaningful aspiration, a of new medicines. Amgen delivered a one-year total well-defined set of values, and a carefully considered $22.8 billion shareholder return of 22% and a five-year return of strategy. Amgen has all of these things, and I’m convinced REVENUE 125%, outperforming the one- and five-year average these will enable us not just to survive but to thrive in total shareholder return of our peer group of 10% and the years ahead. $12.58 101%, respectively. NON-GAAP EARNINGS PER SHARE1 OUR MISSION A Dynamic Environment Amgen’s mission is to serve patients—in particular, 53.5% Amgen was founded in 1980. For most of our history, patients suffering from serious illnesses like NON-GAAP OPERATING MARGIN1 we competed in a handful of specialty therapeutic cardiovascular disease and cancer. We have never categories in which there was relatively little competition. wavered from this mission, and it has never been more $10.5 billion The healthcare ecosystem was fundamentally stable, necessary or urgent. Why? FREE CASH FLOW1 with clearly defined roles for those operating within it. Innovators like Amgen discovered and developed new First and foremost, the world is rapidly aging. For treatments. Physicians and hospitals provided those example, in Amgen’s largest market, the United States, treatments to patients. Governments and insurers paid people over the age of 65 represent the fastest growing for those treatments. segment of the population. It is estimated that an average of 10,000 people will reach the age of 65 every That world no longer exists. day for the next 20 years. Globally, the percentage of people over the age of 65 will roughly double between 1 This is a non-GAAP financial measure. See reconciliation to U.S. generally accepted accounting principles (GAAP) accompanying this letter. 2 now and 2050. For many diseases associated with the Our current portfolio of medicines addresses some of aging process—like cancer, cardiovascular disease, and the world’s leading causes of death. We are passionate Alzheimer’s disease—better, more effective therapies about bringing transformational, not incremental, are needed. innovation to patients in these areas. Innovative new medicines that can prevent disease offer the prospect Even as the world is growing older, approximately 160 of a better future for patients and society. million additional people join the global middle class every year. With this trend, we can unfortunately expect OUR ASPIRATION to see growth in diseases such as diabetes, obesity, Our aspiration is to be the world’s best human and kidney disease, which are more prevalent among therapeutics company. To be the best, we need to first-world countries, and respiratory diseases, which aim high and take on the tough challenges. As an arise with increased urbanization. example, we have seen a number of our peers abandon This growing global burden of disease takes an their efforts to develop new treatments for neurological enormous human toll, of course, but also creates a huge disorders such as Alzheimer’s, a disease that afflicts financial burden on society. To give just one example, 1 in 10 people age 65 and older. Without a doubt, cardiovascular disease now claims a staggering 17.7 Alzheimer’s has proven to be an incredibly difficult million lives a year globally and costs nearly $600 billion target. Nonetheless, we remain in the fight. We are a year in the U.S. alone. working on a variety of mechanisms in Alzheimer’s disease, including a molecule being tested in patients No one company can solve these massive health with a very high genetic risk for Alzheimer’s who have challenges single-handedly, but Amgen is committed yet to develop cognitive symptoms of the disease—a to being an important part of the solution. We have promising new approach. been at the forefront in implementing innovative value- based contracts with insurers to share accountability OUR VALUES for health results and link the price of our medicines to THE AMGEN VALUES The Amgen Values were formalized more than 20 years their performance. For example, our partnership with ago to preserve the entrepreneurial spirit, energy, and Be Science-Based Harvard Pilgrim Health Care provides them a rebate high ethical standards that characterized the early of the cost of Repatha®, our medicine to reduce heart Compete Intensely startup years at our company. These values continue attacks and strokes, for eligible patients who have and Win to guide the way we do business today, and they keep us such events. grounded and unified, especially during turbulent times. Create Value for In addition, Amgen remains deeply committed to long- Patients, Staff, For example, one of our values is to “trust and respect standing patient support programs in the U.S., such as and Stockholders each other.” It sounds obvious, perhaps, but far too the Amgen Safety Net Foundation, that help patients many companies recently have failed to create an Be Ethical with no or limited drug coverage access our medicines. environment in which people from diverse backgrounds For eligible patients unable to afford their prescribed can work together comfortably and collaboratively to Trust and Respect Amgen medicines, we provide our medicines at no cost. achieve great things. Each Other We also support compassionate use and expanded access to our medicines for qualified patients globally. Amgen’s first product, EPOGEN®, was discovered in Ensure Quality 1983 by a team led by a young Taiwanese immigrant Finally, we are also applying our biomanufacturing Work in Teams to the U.S. named Fu-Kuen Lin, so we have long expertise to the development of high-quality, branded understood the importance of harnessing diversity Collaborate, biosimilars, which offer the promise of improved supply to make a difference for patients. Today, more than Communicate, and affordability for certain biologic medicines whose and Be Accountable patents have expired. 3 50% of our employees globally are women, and Bringing Innovative Medicines to Patients 35% of our employees in the U.S. are minorities. We Innovative medicines are the heart and soul of our have approximately 4,000 staff members globally business. If we don’t advance innovative medicines, participating in nine employee resource groups— manufacture them to a high quality standard, and including the Amgen Veterans Employee Network, get them into the hands of patients who need them, shown below observing Veterans Day—that are nothing else we do matters. In 2017, we secured 80 dedicated to supporting their members, our business, approvals for new medicines and new indications in over and the community. 30 countries around the world, continuing a significant shift in our portfolio on two important dimensions. First, the balance of our portfolio is shifting to newer products with very favorable long-term growth potential. For example, three of our currently marketed products— Repatha®, Prolia®, and KYPROLIS®—can benefit significantly more patients than they do today. Together, these three products generated more than $3 billion in sales in 2017 and collectively grew by over 25% year-over-year. • Repatha is our LDL cholesterol treatment to reduce heart attacks and strokes in patients with established cardiovascular disease. Sales of Repatha increased 126% in 2017. In the U.S., someone has a heart attack or stroke every 40 seconds, and nearly In 2017, Amgen received a perfect score on the one in three of these patients will have another event. Corporate Equality Index, which rates corporate policies In December, the U.S. Food and Drug Administration and practices related to LGBTQ workplace equality. (FDA) approved the inclusion of our cardiovascular In early 2018, Amgen ranked among the top 100 on outcomes data in the label for Repatha. With this Forbes magazine’s inaugural list of “America’s Best approval, Repatha became the first PCSK9 inhibitor Employers for Diversity.” We see our commitment to proven to reduce the risk of heart attack (by 27%), diversity as a strength to build upon as we serve an stroke (by 21%), and coronary revascularization increasingly diverse patient population. (by 22%) in adults with established cardiovascular OUR STRATEGY disease. Since receiving the expanded label, we’ve redoubled our efforts to work with large insurers and At Amgen, our strategy is the integrated set of actions pharmacy benefit managers to help patients who are Six therapeutic areas we are taking to grow our company and strengthen our prescribed Repatha by their doctors get it. form the core of our long-term competitive position. Six therapeutic areas form the core of our business: cardiovascular, oncology/ • Prolia is our medicine to reduce the risk of fracture business: cardiovascular, hematology, neuroscience, inflammation, nephrology, in postmenopausal women with osteoporosis.
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • Treatment of MDS in 2014 and Beyond Treatment Goals in MDS
    5/22/2014 Treatment of MDS in 2014 and Beyond Treatment goals in MDS • Get rid of it May 17, 2014 • If you can’t do that, make life better and longer – Improve blood counts Gail J. Roboz, M.D. – Improve quality of life Director, Leukemia Program – Decrease time to progression/leukemia Associate Professor of Medicine Hematopoietic Growth Factors: Hematopoietic Growth Factors: What are they? What are they? • Erythropoietin (EPO,Procrit®, Epogen®) – red • Synthetic versions of proteins normally • Granulocyte colony stimulating factor (GCSF, made in the body to stimulate growth of red Neupogen®) – white cells, white cells and platelets • Granulocyte-macrophage colony stimulating • Promote growth and differentiation factor (GM-CSF, Leukine®) – white • Thrombopoietin (TPO, romiplostim, Nplate®) – • Inhibitors of apoptosis (cell death) platelets • Darbepoietin (Aranesp®) • Peg-filgrastim (Neulasta®) • Note, these are not FDA-approved for MDS Erythropoietin (epo) in MDS Erythropoietin (epo) in MDS • Anemia is presents in >80% of MDS pts at dx • Often high endogenous epo levels • Transfusions help, but many issues • Many different doses and schedules • Recombinant EPO is FDA-approved for treating • Higher response rates with epo + G-CSF if anemia associated with kidney failure epo ≤500 mU/mL and transfusions <2 • Has been used since about 1990 in MDS U/month • Response rates in about 15-30% of patients • Poor probability of response if epo >500 • Many different studies including >1000 patients mU/mL and transfusions >2 U/month • Part of the NCCN MDS treatment guidelines 1. Casadevall N, et al. Blood. 2004;104:321-327. 2. Hellstrom-Lindberg E. Br J Haematol. 1995;89:67-71.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Atopic Dermatitis (AD)
    This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by education grants from AbbVie, Inc., Sanofi Genzyme and Regeneron Pharmaceuticals. © 2019 PRIME® Education, LLC. All Rights Reserved.. Overview This downloadable fact‐sheet provides an easy‐to‐follow collection of the latest evidence shaping the treatment and management of psoriasis (PsO) and atopic dermatitis (AD). Learn about validated tools, evidence‐based strategies, and new and emerging targeted therapies that can be incorporated in daily practice to improve outcomes for patients with these conditions. © 2019 PRIME® Education, LLC. All Rights Reserved.. 2 1 Learning Objectives • Identify major barriers to evidence‐based treatment and management in federal and public sectors • Implement appropriate methods for diagnosis and assessment of disease activity • Assess current evidence on targeted biologic and small‐molecule therapies to guide treatment decisions for patients with moderate to severe disease • Monitor treatment responses according to treat‐to‐target principles and methods • Apply current evidence and guidelines to inform treatment decisions for patients with inadequate responses to initial therapies • Incorporate patient‐reported outcomes and shared decision‐making into clinical practice • Apply effective strategies for multidisciplinary care coordination and shared patient management © 2019 PRIME® Education, LLC. All Rights Reserved.. 3 Accreditation In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team, and learners will receive 2.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
    [Show full text]
  • HEALTH BENEFITS Providing Value for Our Employees
    HEALTH BENEFITS Providing Value for Our Employees March 2017 Business Roundtable CEO members lead companies with more than $6 trillion in annual revenues and nearly 15 million employees. The combined market capitalization of Business Roundtable member companies is the equivalent of nearly one-quarter of total U.S. stock market capitalization, and Business Roundtable members invest $103 billion annually in research and development — equal to 30 percent of U.S. private R&D spending. Our companies pay $226 billion in dividends to shareholders and generate $412 billion in revenues for small and medium-sized businesses annually. Business Roundtable companies also make more than $7 billion a year in charitable contributions. Please visit us at www.brt.org, check us out on Facebook and LinkedIn, and follow us on Twitter. Copyright © 2017 by Business Roundtable HEALTH BENEFITS Providing Value for Our Employees March 2017 March 2017 DEAR BUSINESS LEADERS AND STAKEHOLDERS: I am pleased to share with you a new report highlighting what leading U.S. companies are doing to improve health outcomes for our employees and their families. America’s employer-sponsored health benefits system is the foundation of health care in the United States. Of the 209 million Americans who are covered by health insurance plans, 85 percent — or 177 million Americans* — receive health coverage through an employer. This report demonstrates many different ways employers are helping to drive a health care system that delivers better health care quality and value. I hope you find this report helpful. Sincerely, Brian Moynihan Chairman and Chief Executive Officer Bank of America * Bureau of Labor Statistics, Health Insurance Coverage in the United States: 2015, Current Population Reports, September 2016.
    [Show full text]
  • Smoldering Inflammation in Cardio-Immune-Metabolic Disorders
    EDITORIAL published: 19 March 2021 doi: 10.3389/fphys.2021.651946 Editorial: Smoldering Inflammation in Cardio-Immune-Metabolic Disorders Gilda Varricchi 1,2,3*, Nazareno Paolocci 4,5, Felice Rivellese 6 and Giuseppe Rengo 1,7 1 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy, 2 Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy, 3 Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council, Naples, Italy, 4 Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States, 5 Department of Biomedical Sciences, University of Padova, Padova, Italy, 6 Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 7 Istituti Clinici Scientifici Maugeri SpA Società Benefit, Telese Terme, Italy Keywords: allergic disorders, diabetes, obesity, low grade inflammation, sinovitis, IL-5, mast cells, Alzheimer’s disease Editorial on the Research Topic Smoldering Inflammation in Cardio-Immune-Metabolic Disorders “If many remedies are prescribed for an illness, you may be certain that the illness has no cure.” Anton Chekhov - The Cherry Orchard - Smoldering or low-grade inflammation plays a pivotal role in both physiological and pathological conditions (Calder et al., 2017; Zelechowska et al., 2018; Ronnback and Hansson, 2019). Aging is accompanied by
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • S. No. Name of the Firm Date of Permission No. Name of the Indication Dosage Form & Strength
    List of new drugs (r-DNA origin) approved for mannufacture and marketing in India for the Year 2021 S. No. Name of the firm Date of Permission No. Name of the Indication Dosage Form & Strength Rheumatoid Arthritis (RA)–Etanercept in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.Etanercept can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriateEtanercept is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Etanercept, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical functionJuvenile Idiopathic Arthritis (JIA) – Treatment of polyarthritis (rheumatoid factor positive or negative)and extended oligoarthritis in children and adolescents from the age of 2 years who have had aninadequate response to, or who have proved intolerant of, methotrexate.Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response Solution for subcutaneous Injection (single use)Pre- Mylan Pharmaceuticals to, or who have proved intolerant of, conventional therapy.Etanercept has not been studied in children aged less than 2 filled syringe:(i). 50 mg/mL in Prefilled Syringes(ii).
    [Show full text]
  • Novel Concepts of Treatment for Patients with Myelofibrosis And
    cancers Review Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms Prithviraj Bose * , Lucia Masarova and Srdan Verstovsek Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; [email protected] (L.M.); [email protected] (S.V.) * Correspondence: [email protected] Received: 30 August 2020; Accepted: 1 October 2020; Published: 9 October 2020 Simple Summary: Myelofibrosis (MF) is an advanced form of a group of rare, related bone marrow cancers termed myeloproliferative neoplasms (MPNs). Some patients develop myelofibrosis from the outset, while in others, it occurs as a complication of the more indolent MPNs, polycythemia vera (PV) or essential thrombocythemia (ET). Patients with PV or ET who require drug treatment are typically treated with the chemotherapy drug hydroxyurea, while in MF, the targeted therapies termed Janus kinase (JAK) inhibitors form the mainstay of treatment. However, these and other drugs (e.g., interferons) have important limitations. No drug has been shown to reliably prevent the progression of PV or ET to MF or transformation of MPNs to acute myeloid leukemia. In PV, it is not conclusively known if JAK inhibitors reduce the risk of blood clots, and in MF, these drugs do not improve low blood counts. New approaches to treating MF and related MPNs are, therefore, necessary. Abstract: Janus kinase (JAK) inhibition forms the cornerstone of the treatment of myelofibrosis (MF), and the JAK inhibitor ruxolitinib is often used as a second-line agent in patients with polycythemia vera (PV) who fail hydroxyurea (HU). In addition, ruxolitinib continues to be studied in patients with essential thrombocythemia (ET).
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]